Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

KEDRION BIOPHARMA

NIF 980701996
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €725,289 24 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €725,289 24 contracts
A2 · Late Publication €2,027,302,815 189 contracts
Contract published to BASE more than 10 days after the signing date
LOW €2,027,302,815 189 contracts
A5 · Threshold Splitting €21,380,782 9 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €21,380,782 9 contracts
A6 · Low Competition €6,210 1 contracts
Only one bidder participated in a competitive procedure
MEDIUM €6,210 1 contracts
A9 · Abnormal Price Reduction €2,485,020,550 140 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €2,485,020,550 140 contracts
C3 · Missing Mandatory Fields €10,928 4 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €10,928 4 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

14
€274,253,430
7
€177,094,201
15
€174,781,420
10
€168,493,126
7
€137,233,281
5
€129,970,095
21
€127,082,646
7
€116,646,477
32
€115,328,518
6
€113,238,243
3
€83,519,053
10
€82,453,826
3
€78,655,867
4
€75,429,788
3
€72,235,017
5
€72,094,769
2
€71,576,022
2
€53,791,412
1
€53,753,987
3
€53,391,521
Page 1 of 3 · 41 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 1 · 9 contracts

Aquisição de IMUNOGLOBULINA HUMANA, IV, 50MG/ML;200ML, ao Lab. Kedrion, para a ULSASI, para o ano 2024
PT · 10931729 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€74,800 2024-09-20
Aquisição de IMUNOGLOBULINA HUMANA, IV, 50MGML;200ML ao Lab. Kedrion para a ULSASI para o ano de 2024
PT · 10911541 · Ajuste Direto Regime G...
A5 · Threshold Splitting
€19,800 2024-09-06
460/2023 - Convite ao abrigo do(s) acordo(s)-quadro 2020/9 - Derivados do plasma humano e 2021/55 - Medicamentos diversos para suprir necessidades na área da saúde
PT · 10424087 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€5,275,988 2023-05-24
460/2023 - Convite ao abrigo do(s) acordo(s)-quadro 2020/9 - Derivados do plasma humano e 2021/55 - Medicamentos diversos para suprir necessidades na área da saúde
PT · 10058367 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€5,275,988 2023-05-05
460/2023 - Convite ao abrigo do(s) acordo(s)-quadro 2020/9 - Derivados do plasma humano e 2021/55 - Medicamentos diversos para suprir necessidades na área da saúde
PT · 10324792 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€5,275,988 2023-05-04
460/2023 - Convite ao abrigo do(s) acordo(s)-quadro 2020/9 - Derivados do plasma humano e 2021/55 - Medicamentos diversos para suprir necessidades na área da saúde
PT · 10196118 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€5,275,988 2023-05-04
MEDICAMENTOS
PT · 9335995 · Ajuste Direto Regime G...
A5 · Threshold Splitting A2 · Late Publication
€19,195 2022-04-21
41/628/2022 - Derivados do Plasma
PT · 9390284 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication
€143,509 2022-02-10
SPMS (2020/009) DERIVADOS DO PLASMA HUMANO
PT · 9253177 · Ao abrigo de acordo-qu...
A5 · Threshold Splitting A2 · Late Publication +1
€19,526 2022-02-04
Overview
Total Value Won
€2,501,515,647
Contracts Won
279
Score 10575 · CRITICAL RISK
NIF
980701996
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

No director data imported yet.

Director and fiscal identity data for Portuguese companies can be found in the Registo Comercial (publicacoes.mj.pt).

Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned